The GLP-1 Paradox: MassHealth Cuts Coverage as Obesity Drugs Strain Budgets

MassHealth Pulls GLP-1 Coverage, Exposing a National Affordability Crisis

The US healthcare system is grappling with an impossible choice. Drugs in the GLP-1 class – from Ozempic to Wegovy – deliver undeniable health benefits for obesity and related chronic conditions, but their price tags are so steep that government and employer plans are starting to walk away.

This month, MassHealth, Massachusetts’ Medicaid program, announced it would stop covering the medications for weight loss. The decision, which affects roughly 22,000 residents, will save the state an estimated $15 million per year. It is a stark example of a dilemma spreading across the country: the drugs are too effective to ignore, yet too expensive to provide to all who could benefit under current budgets.

The retreat is not isolated. Other states and private employers are scaling back access, often pitting advocates for unfettered coverage against those who argue the near-term financial strain is unsustainable. But framing the debate as a binary yes-or-no question, experts contend, risks discarding a treatment that could reduce the downstream costs of diabetes, kidney disease, liver conditions and other obesity-driven illnesses.

The underlying problem is not just the list price of the drugs. It is a delivery system that was never designed to manage a chronic disease as prevalent and complex as obesity. Physicians remain largely untrained in obesity medicine, claims data underrepresent the condition, and the infrastructure to pair medication with behavioral and nutritional support is missing. That mismatch fuels both wasteful prescribing and the temptation to cut coverage outright.

Beyond the Binary: Why the GLP-1 Debate Needs a Scalpel, Not a Hammer

Why the 'Cover or Don't Cover' Approach Fails

The MassHealth decision reflects a broader, binary mindset in health policy – one that treats GLP-1 access as an all-or-nothing proposition. Either plans pay for everyone with a BMI above a certain threshold, or they pay for no one. The result is a roller coaster: broad access collapses under its own cost, patients are abruptly cut off, and public debate polarizes without resolving the underlying economics.

A more nuanced, data-informed approach is possible. The article’s authors, a founder of a health startup and a former HHS chief technology officer, argue for what they call a “smart scalpel” strategy. By analyzing claims data, payers can identify the individuals with the highest disease burden – those with severe obesity and multiple comorbidities – and prioritize them for comprehensive treatment. That targeted spending, they contend, can generate enough near-term medical savings to fund the program sustainably, then be expanded to earlier interventions.

The Missing Infrastructure for Obesity Medicine

A deeper obstacle is that the US healthcare system is still learning how to treat obesity. The American Medical Association recognized obesity as a disease only in 2013, which means most practicing physicians received little formal training in it. As a result, obesity is “woefully underrepresented in claims data,” and there is no established delivery platform to combine medication with nutritional, physical activity and behavioral support.

GLP-1s are a breakthrough, but without the surrounding infrastructure – registered dietitians, behavioral health specialists, remote monitoring – the drugs risk being used as a standalone quick fix, with high dropout rates and weight regain. The real promise lies in multidisciplinary, evidence-backed care programs that track not just weight, but improvements in biomarkers, mobility, pain and mental health.

The Economic Case for Multidisciplinary Care

The argument that targeted GLP-1 use can pay for itself hinges on bending the cost curve for obesity-related complications. A person with severe obesity and uncontrolled diabetes incurs enormous medical costs; effective weight loss can reduce hospitalizations, medication needs and disease progression. The startup Ilant, mentioned in the article, reports early data showing improvements in physical health and even reductions in loneliness among participants in such programs.

Yet the clock is ticking. The authors note that the Bridge program – a temporary coverage mechanism that currently supports many patients – is an 18-month initiative without a clear successor. If policymakers and employers do not replace binary coverage decisions with risk-stratified, value-based models before that window closes, the financial pressure will almost certainly lead to more MassHealth-style cuts, deepening health inequities and forfeiting the long-term savings GLP-1s could unlock.

Forging a Financially Sustainable Obesity Care Model

• Adopt risk-stratified coverage. Instead of covering all-comers or no one, use claims data to identify and prioritize patients with the greatest unmet medical need – for example, those with a BMI over 35 and uncontrolled type 2 diabetes. The MassHealth cut illustrates what happens when broad access becomes fiscally untenable.
• Build the multidisciplinary infrastructure alongside the drug. Plans should contract for programs that integrate GLP-1s with behavioral therapy, nutrition counseling and remote monitoring. Ilant’s early results suggest that this approach can move the needle on physical function and mental well-being, not just weight alone.
• Plan for the post-Bridge reality. The temporary coverage expansion known as the Bridge program ends in 18 months. Employers and state Medicaid programs should model their cost projections now and explore value-based contracts with manufacturers that tie reimbursement to real-world health outcomes.
• Track a broader set of outcomes. Move beyond BMI as the sole metric. Monitor changes in HbA1c, blood pressure, pain scores, activity levels and mental health indicators to build the evidence base that targeted GLP-1 spending generates a positive return on investment over two to three years.